<p>Avalo Therapeutics（納斯達克股票代碼：AVTX - 獲取免費報告）在週四向投資者發佈的一份報告中，投資分析師 Citizens Jmp 將其目標價格從 62.00 美元下調至 55.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “市場表現優於大盤”。Citizens Jmp 的目標價格意味着該股票相較於之前的收盤價有 182.85% 的潛在上漲空間。</p>
<p>獲取 <strong>Avalo Therapeutics</strong> 的提醒：</p>
<p>其他一些分析師最近也對 AVTX 發表了看法。華爾街 Zen 在 3 月 29 日的研究報告中將 Avalo Therapeutics 的股票評級從 “強烈賣出” 上調至 “持有”。Wolfe Research 在 4 月 9 日的報告中開始覆蓋 Avalo Therapeutics，給予 “表現優於大盤” 的評級，並設定 48.00 美元的目標價格。Guggenheim 在 2 月 2 日的報告中開始覆蓋 Avalo Therapeutics，給予 “買入” 評級，並設定 50.00 美元的目標價格。花旗集團在 5 月 6 日的研究報告中重申了 Avalo Therapeutics 的 “表現優於大盤” 評級。最後，HC Wainwright 在週四的研究報告中將 Avalo Therapeutics 的目標價格從 40.00 美元下調至 35.00 美元，並對該股票設定 “買入” 評級。共有 11 位分析師對該股票給予 “買入” 評級，1 位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，Avalo Therapeutics 目前的共識評級為 “適度買入”，共識目標價格為 48.13 美元。</p>
<p><strong>閲讀我們對 AVTX 的最新股票分析</strong></p>
<h2>Avalo Therapeutics 股價下跌 2.0%</h2>
<p>在週四的午盤交易中，AVTX 股票下跌 0.41 美元，報 19.45 美元。該股票的交易量為 195,228 股，而其平均交易量為 1,002,079 股。該公司的市值為 5.7032 億美元，市盈率為-3.42，貝塔值為 0.78。Avalo Therapeutics 的 52 周低點為 3.43 美元，52 周高點為 24.27 美元。該股票的 50 日簡單移動平均線為 15.84 美元，200 日簡單移動平均線為 16.44 美元。</p>
<p>Avalo Therapeutics（納斯達克股票代碼：AVTX - 獲取免費報告）最近在 5 月 13 日發佈了季度財報。該公司報告每股收益為-0.98 美元，超出分析師的共識預期（-1.00 美元）0.02 美元。平均而言，股票分析師預測 Avalo Therapeutics 在當前年度的每股收益為-3.1。</p>
<h2>Avalo Therapeutics 的內部交易</h2>
<p>在其他新聞中，首席財務官 Christopher Ryan Sullivan 在 4 月 30 日的交易中出售了 8,457 股該股票。該股票的平均售價為 13.23 美元，總價值為 111,886.11 美元。交易完成後，首席財務官持有 423 股公司股票，價值 5,596.29 美元。這代表其持股比例減少了 95.24%。該交易已在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 Paul Varki 在 5 月 6 日的交易中出售了 75,063 股該股票。該股票的平均售價為 20.17 美元，總價值為 1,514,020.71 美元。交易完成後，該內部人士直接持有 3,634 股公司股票，價值 73,297.78 美元。該交易使其持股比例減少了 95.38%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去 90 天內，內部人士共出售了 138,078 股公司股票，價值 2,501,346 美元。4.46% 的股票由內部人士持有。</p>
<h2>機構投資者對 Avalo Therapeutics 的看法</h2>
<p>大型投資者最近調整了對該公司的持股。Orbimed Advisors LLC 在第三季度將其在 Avalo Therapeutics 的持股增加了 39.5%。Orbimed Advisors LLC 目前擁有 1,349,300 股公司股票，價值 17,150,000 美元，此前在上個季度增持了 382,300 股。Nantahala Capital Management LLC 在第三季度將其在 Avalo Therapeutics 的持股增加了 24.1%。Nantahala Capital Management LLC 目前擁有 1,235,000 股公司股票，價值 15,697,000 美元，此前在上個季度增持了 240,000 股。Affinity Asset Advisors LLC 在第四季度將其在 Avalo Therapeutics 的持股增加了 4.5%。Affinity Asset Advisors LLC 目前擁有 1,051,054 股公司股票，價值 19,087,000 美元，此前在該期間增持了 44,837 股。Caligan Partners LP 在第四季度將其在 Avalo Therapeutics 的持股增加了 5.8%。Caligan Partners LP 目前擁有 881,533 股公司股票，價值 16,009,000 美元，此前在上個季度增持了 48,200 股。最後，Balyasny Asset Management L.P.在第三季度獲得了 Avalo Therapeutics 的新股份，價值約 10,390,000 美元。目前 87.06% 的股票由機構投資者持有。</p>
<h2>Avalo Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Avalo Therapeutics 是一家臨牀階段的生物技術公司，專注於心血管代謝、纖維化和炎症疾病的新療法的發現、開發和商業化。該公司的專有藥物設計平台能夠創造具有優化藥代動力學特徵的長效前藥，旨在提高療效、安全性和患者依從性。通過利用這一技術，Avalo 旨在解決現有治療方法未能滿足的疾病進展的關鍵驅動因素。</p>
<p>其主要項目包括 AVTX-002，這是一種首創的前藥候選藥物，旨在抑制腎素原，用於治療高血壓及相關心血管疾病，以及 AVTX-006，這是一種早期候選藥物，針對與纖維化和代謝功能障礙相關的途徑。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Avalo Therapeutics</li>
<li>Chime 最終實現盈利——但風險依然存在</li>
<li>eVTOL 投資：拋棄出租車，購買藍圖</li>
<li>伯克希爾對紐約時報的投資現狀</li>
<li>Affirm 與谷歌的交易旨在影響你的錢包</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Avalo Therapeutics 嗎？</h2>
<p>在考慮 Avalo Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Avalo Therapeutics 並不在名單上。</p>
<p>雖然 Avalo Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AVTX

納斯達克生物科技指數 ETF - iShares Nasdaq

基因改革 ETF - ARK

<p>Citizens Jmp 已將 Avalo Therapeutics (NASDAQ:AVTX) 的目標股價從 62.00 美元下調至 55.00 美元，維持 “市場表現優於大盤” 的評級。這個新目標暗示該股票相較於之前的收盤價有 182.85% 的潛在上漲空間。其他分析師也給出了混合評級，普遍評級為 “適度買入”，目標股價為 48.13 美元。Avalo 的股票目前下跌 2.0%，報 19.45 美元，市值為 5.7032 億美元。近期內部交易顯示高管們進行了大量的股票出售</p>

<p>Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) had its price objective decreased by investment analysts at Citizens Jmp from $62.00 to $55.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's target price points to a potential upside of 182.85% from the stock's previous close.</p>
<div class="lb-trans"><p>Avalo Therapeutics（納斯達克股票代碼：AVTX - 獲取免費報告）在週四向投資者發佈的一份報告中，投資分析師 Citizens Jmp 將其目標價格從 62.00 美元下調至 55.00 美元，Benzinga 報道。該公司目前對該股票的評級為 “市場表現優於大盤”。Citizens Jmp 的目標價格意味着該股票相較於之前的收盤價有 182.85% 的潛在上漲空間。</p>
</div><p>Get <strong>Avalo Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Avalo Therapeutics</strong> 的提醒：</p>
</div><p>A number of other analysts have also recently weighed in on AVTX. Wall Street Zen raised shares of Avalo Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, March 29th. Wolfe Research began coverage on Avalo Therapeutics in a report on Thursday, April 9th. They set an &#34;outperform&#34; rating and a $48.00 price objective on the stock. Guggenheim initiated coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a &#34;buy&#34; rating and a $50.00 target price for the company. Citigroup restated an &#34;outperform&#34; rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Finally, HC Wainwright lowered their price target on Avalo Therapeutics from $40.00 to $35.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Avalo Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $48.13.</p>
<div class="lb-trans"><p>其他一些分析師最近也對 AVTX 發表了看法。華爾街 Zen 在 3 月 29 日的研究報告中將 Avalo Therapeutics 的股票評級從 “強烈賣出” 上調至 “持有”。Wolfe Research 在 4 月 9 日的報告中開始覆蓋 Avalo Therapeutics，給予 “表現優於大盤” 的評級，並設定 48.00 美元的目標價格。Guggenheim 在 2 月 2 日的報告中開始覆蓋 Avalo Therapeutics，給予 “買入” 評級，並設定 50.00 美元的目標價格。花旗集團在 5 月 6 日的研究報告中重申了 Avalo Therapeutics 的 “表現優於大盤” 評級。最後，HC Wainwright 在週四的研究報告中將 Avalo Therapeutics 的目標價格從 40.00 美元下調至 35.00 美元，並對該股票設定 “買入” 評級。共有 11 位分析師對該股票給予 “買入” 評級，1 位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，Avalo Therapeutics 目前的共識評級為 “適度買入”，共識目標價格為 48.13 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AVTX</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 AVTX 的最新股票分析</strong></p>
</div><h2>Avalo Therapeutics Trading Down 2.0%</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 股價下跌 2.0%</h2>
</div><p>AVTX stock traded down $0.41 during midday trading on Thursday, hitting $19.45. The stock had a trading volume of 195,228 shares, compared to its average volume of 1,002,079. The firm has a market capitalization of $570.32 million, a price-to-earnings ratio of -3.42 and a beta of 0.78. Avalo Therapeutics has a 52 week low of $3.43 and a 52 week high of $24.27. The stock has a 50-day simple moving average of $15.84 and a 200 day simple moving average of $16.44.</p>
<div class="lb-trans"><p>在週四的午盤交易中，AVTX 股票下跌 0.41 美元，報 19.45 美元。該股票的交易量為 195,228 股，而其平均交易量為 1,002,079 股。該公司的市值為 5.7032 億美元，市盈率為-3.42，貝塔值為 0.78。Avalo Therapeutics 的 52 周低點為 3.43 美元，52 周高點為 24.27 美元。該股票的 50 日簡單移動平均線為 15.84 美元，200 日簡單移動平均線為 16.44 美元。</p>
</div><p>Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. On average, equities analysts forecast that Avalo Therapeutics will post -3.1 EPS for the current year.</p>
<div class="lb-trans"><p>Avalo Therapeutics（納斯達克股票代碼：AVTX - 獲取免費報告）最近在 5 月 13 日發佈了季度財報。該公司報告每股收益為-0.98 美元，超出分析師的共識預期（-1.00 美元）0.02 美元。平均而言，股票分析師預測 Avalo Therapeutics 在當前年度的每股收益為-3.1。</p>
</div><h2>Insider Transactions at Avalo Therapeutics</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 的內部交易</h2>
</div><p>In other news, CFO Christopher Ryan Sullivan sold 8,457 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the transaction, the chief financial officer owned 423 shares of the company's stock, valued at $5,596.29. This represents a 95.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total value of $1,514,020.71. Following the completion of the transaction, the insider directly owned 3,634 shares in the company, valued at $73,297.78. The trade was a 95.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 138,078 shares of company stock worth $2,501,346 over the last 90 days. 4.46% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席財務官 Christopher Ryan Sullivan 在 4 月 30 日的交易中出售了 8,457 股該股票。該股票的平均售價為 13.23 美元，總價值為 111,886.11 美元。交易完成後，首席財務官持有 423 股公司股票，價值 5,596.29 美元。這代表其持股比例減少了 95.24%。該交易已在向 SEC 提交的文件中披露，文件可通過此超鏈接獲取。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 Paul Varki 在 5 月 6 日的交易中出售了 75,063 股該股票。該股票的平均售價為 20.17 美元，總價值為 1,514,020.71 美元。交易完成後，該內部人士直接持有 3,634 股公司股票，價值 73,297.78 美元。該交易使其持股比例減少了 95.38%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去 90 天內，內部人士共出售了 138,078 股公司股票，價值 2,501,346 美元。4.46% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Avalo Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Avalo Therapeutics 的看法</h2>
</div><p>Large investors have recently modified their holdings of the business. Orbimed Advisors LLC increased its position in shares of Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company's stock worth $17,150,000 after acquiring an additional 382,300 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company's stock valued at $15,697,000 after acquiring an additional 240,000 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in Avalo Therapeutics by 4.5% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company's stock worth $19,087,000 after purchasing an additional 44,837 shares during the period. Caligan Partners LP increased its holdings in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company's stock worth $16,009,000 after purchasing an additional 48,200 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Avalo Therapeutics in the 3rd quarter valued at approximately $10,390,000. 87.06% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該公司的持股。Orbimed Advisors LLC 在第三季度將其在 Avalo Therapeutics 的持股增加了 39.5%。Orbimed Advisors LLC 目前擁有 1,349,300 股公司股票，價值 17,150,000 美元，此前在上個季度增持了 382,300 股。Nantahala Capital Management LLC 在第三季度將其在 Avalo Therapeutics 的持股增加了 24.1%。Nantahala Capital Management LLC 目前擁有 1,235,000 股公司股票，價值 15,697,000 美元，此前在上個季度增持了 240,000 股。Affinity Asset Advisors LLC 在第四季度將其在 Avalo Therapeutics 的持股增加了 4.5%。Affinity Asset Advisors LLC 目前擁有 1,051,054 股公司股票，價值 19,087,000 美元，此前在該期間增持了 44,837 股。Caligan Partners LP 在第四季度將其在 Avalo Therapeutics 的持股增加了 5.8%。Caligan Partners LP 目前擁有 881,533 股公司股票，價值 16,009,000 美元，此前在上個季度增持了 48,200 股。最後，Balyasny Asset Management L.P.在第三季度獲得了 Avalo Therapeutics 的新股份，價值約 10,390,000 美元。目前 87.06% 的股票由機構投資者持有。</p>
</div><h2>Avalo Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.</p>
<div class="lb-trans"><p>Avalo Therapeutics 是一家臨牀階段的生物技術公司，專注於心血管代謝、纖維化和炎症疾病的新療法的發現、開發和商業化。該公司的專有藥物設計平台能夠創造具有優化藥代動力學特徵的長效前藥，旨在提高療效、安全性和患者依從性。通過利用這一技術，Avalo 旨在解決現有治療方法未能滿足的疾病進展的關鍵驅動因素。</p>
</div><p>Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.</p>
<div class="lb-trans"><p>其主要項目包括 AVTX-002，這是一種首創的前藥候選藥物，旨在抑制腎素原，用於治療高血壓及相關心血管疾病，以及 AVTX-006，這是一種早期候選藥物，針對與纖維化和代謝功能障礙相關的途徑。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Avalo Therapeutics</li>
<li>Chime Finally Turns Profitable—But Risks Remain</li>
<li>eVTOL Investing: Ditch the Taxi, Buy the Blueprint</li>
<li>How Berkshire’s New York Times Bet Looks Today</li>
<li>Affirm's Google Deal Aims for Your Wallet</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Avalo Therapeutics</li>
<li>Chime 最終實現盈利——但風險依然存在</li>
<li>eVTOL 投資：拋棄出租車，購買藍圖</li>
<li>伯克希爾對紐約時報的投資現狀</li>
<li>Affirm 與谷歌的交易旨在影響你的錢包</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Avalo Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Avalo Therapeutics 嗎？</h2>
</div><p>Before you consider Avalo Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Avalo Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Avalo Therapeutics 並不在名單上。</p>
</div><p>While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Avalo Therapeutics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00

Market Beat

Avalo Therapeutics

Citizens Financial

花旗

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Citizens Jmp 將 Avalo Therapeutics（NASDAQ 代碼：AVTX）的目標股價下調至 55.00 美元